Understand the source comparison
Best Research Peptides for Hashimoto's Research: Mechanism Comparison
Thymosin Alpha-1 T-regulatory cell upregulation, Treg/Th17 rebalancing Direct (restores immune tolerance) Indirect (reduces ongoing damage) Minimal direct effect Phase 2 human trials in autoimmune thyroiditis BPC-157 VEGF/FGF-2 upregulation, fibroblast activat
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Thymosin Alpha-1
- T-regulatory cell upregulation, Treg/Th17 rebalancing
- Direct (restores immune tolerance)
- Indirect (reduces ongoing damage)
- Minimal direct effect
- Phase 2 human trials in autoimmune thyroiditis
- BPC-157
- VEGF/FGF-2 upregulation, fibroblast activation
- Indirect (anti-inflammatory cytokine modulation)
- Direct (accelerates follicular repair, reduces fibrosis)
- Supports metabolic function indirectly via tissue health
- Preclinical models, anecdotal human use
- Selank
- GABA-A modulation, IL-6/TNF-α downregulation
- Moderate (cytokine normalization without immunosuppression)
- Minimal
- Stress-axis regulation (HPA normalization)
- Preclinical autoimmune models, no Hashimoto's-specific trials
- MOTS-c
- AMPK activation, insulin sensitivity enhancement
- Minimal direct immune effect
- Indirect (oxidative stress reduction supports cell viability)
- Direct (improves glucose metabolism, mitochondrial respiration)
- Metabolic syndrome trials, no Hashimoto's-specific data
- Thymosin Beta-4
- Actin regulation, TGF-β1 suppression, stem cell recruitment
- Moderate (anti-inflammatory)
- Direct (anti-fibrotic, promotes follicular regeneration)
- Indirect via improved tissue function
- Preclinical thyroiditis models
- Professional Assessment
- Thymosin Alpha-1 holds strongest immune-modulation evidence for Hashimoto's. BPC-157 best supports structural repair post-damage. MOTS-c addresses metabolic dysfunction when TSH normalization fails to resolve fatigue.